NASDAQ:INMB

INmune Bio (INMB) Stock Forecast, Price & News

$6.85

-0.16 (-2.28%)

(As of 01:04 PM ET)

Compare

Today's Range: $6.75
▼
$7.45
50-Day Range: $6.61
▼
$8.95
52-Week Range: $5.75
▼
$11.26

Volume: 26,389 shs
Average Volume: 53,970 shs
Market Capitalization: $123.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $16.00

INmune Bio MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 129.9% Upside
$16.00 Price Target
Short Interest: Bearish
11.51% of Float Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: N/A
Insider Trading: Selling Shares
$110,100 Sold Last Quarter
Proj. Earnings Growth: N/A

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.86 out of 5 stars

Medical Sector

767th out of 972 stocks

Biological Products, Except Diagnostic Industry

124th out of 158 stocks

3.5

Analyst's Opinion

Consensus Rating
INmune Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $16.00, INmune Bio has a forecasted upside of 129.9% from its current price of $6.96.
Amount of Analyst Coverage
INmune Bio has received no research coverage in the past 90 days.

1.0

Short Interest

Percentage of Shares Shorted
11.51% of the float of INmune Bio has been sold short.
Short Interest Ratio / Days to Cover
INmune Bio has a short interest ratio ("days to cover") of 19.6, which indicates bearish sentiment.
Change versus previous month
Short interest in INmune Bio has recently decreased by 1.75%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
INmune Bio does not currently pay a dividend.
Dividend Growth
INmune Bio does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for INMB.

2.7

News and Social Media Coverage

News Sentiment
INmune Bio has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 1 news article for INmune Bio this week, compared to 1 article on an average week.
Search Interest
Only 1 people have searched for INMB on MarketBeat in the last 30 days. This is a decrease of -67% compared to the previous 30 days.

2.5

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, INmune Bio insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $110,100.00 in company stock.
Percentage Held by Insiders
36.10% of the stock of INmune Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
Only 12.13% of the stock of INmune Bio is held by institutions.

0.0

Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of INmune Bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of INmune Bio is -4.73, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
INmune Bio has a P/B Ratio of 2.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About INmune Bio (NASDAQ:INMB) Stock

INmune Bio, Inc., a clinical-stage immunology company, focuses on reprogramming the patient's innate immune system to treat cancer and neurodegenerative diseases. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which focuses on treating women with relapse refractory ovarian carcinoma solid tumor and patients with high-risk myelodysplastic syndrome; INB03 to treat patients with cancers that express MUC4, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers; and XPro1595 for the treatment of Alzheimer's disease and Treatment Resistant Depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. The company was incorporated in 2015 and is headquartered in Boca Raton, Florida.

INMB Price History

30 days | 90 days | 365 days | Advanced Chart

INMB Stock News Headlines

September 7, 2023 | finance.yahoo.com

INmune Bio Inc. to Present at Baird Global Healthcare Conference and H.C Wainwright 25th Annual Global Investment Conference

September 6, 2023 | markets.businessinsider.com

Inmune Bio (INMB) Receives a Buy from BTIG

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

September 5, 2023 | finance.yahoo.com

INmune Bio Inc. Announces Approval of Clinical Trial Application by the U.K. Medicines and Healthcare Products Regulatory Agency for Phase 2 Clinical Trial in Alzheimer’s Disease

August 27, 2023 | finance.yahoo.com

Retail investors account for 44% of INmune Bio, Inc.'s (NASDAQ:INMB) ownership, while insiders account for 29%

August 8, 2023 | finance.yahoo.com

INmune Bio, Inc. (NASDAQ:INMB) Q2 2023 Earnings Call Transcript

August 8, 2023 | finance.yahoo.com

Q2 2023 INmune Bio Inc Earnings Call

August 7, 2023 | msn.com

INmune Bio GAAP EPS of -$0.36 beats by $0.04

September 29, 2023 | PressReach (Ad)

This Stock's a Sleeping Giant

The stock everyone has their eye on - discover why it's the talk of the investment world.

August 7, 2023 | finance.yahoo.com

INmune Bio Inc. Announces Second Quarter 2023 Results and Provides Business Update

August 4, 2023 | benzinga.com

Earnings Outlook For INmune Bio

August 1, 2023 | finance.yahoo.com

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

August 1, 2023 | finance.yahoo.com

INmune Bio Inc. to Present at the BTIG Virtual Biotechnology Conference

July 31, 2023 | finance.yahoo.com

INmune Bio, Inc. to Report Second Quarter 2023 Financial Results and Provide a Corporate Update on Monday, August 7

July 29, 2023 | markets.businessinsider.com

Maxim Group Sticks to Its Buy Rating for Inmune Bio (INMB)

July 12, 2023 | finance.yahoo.com

INmune Bio Inc. to Deliver Keynote Talk at 5th World Aging and Rejuvenation Conference.

July 11, 2023 | finance.yahoo.com

INmune Bio Inc. Announces Novel MRI Biomarker Data Demonstrating Improvement in Gray Matter in Patients with Alzheimer’s Disease

July 10, 2023 | finance.yahoo.com

INmune Bio Inc. Announces Data Presented at the 16th European Meeting on Glial Cells in Health and Disease Shows that XPro™ Promotes Remyelination by Affecting Astroglial and Microglial Biology

June 13, 2023 | benzinga.com

INmune Bio – Helping Your Own Cells Fight Cancer And Reverse Alzheimer's Disease

June 2, 2023 | proactiveinvestors.com

INmune Bio's Alzheimer's treatment merits a high-upside price target, analysts say

May 24, 2023 | technews.tmcnet.com

INmune Bio Inc.'s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

May 24, 2023 | finance.yahoo.com

INmune Bio Inc.’s Chief Scientific Officer, Mark Lowdell, Ph.D. to Present Plenary Talk at International Society of Cell & Gene Therapy

May 13, 2023 | marketwatch.com

8-K: Inmune Bio, Inc.

May 9, 2023 | markets.businessinsider.com

Analysts Offer Insights on Healthcare Companies: Baxter International (BAX), Cerus (CERS) and Inmune Bio (INMB)

May 8, 2023 | seekingalpha.com

INmune Bio gets FDA IND approval for prostate cancer immunotherapy

May 8, 2023 | finance.yahoo.com

INmune Bio, Inc. Announces FDA Clearance of IND Application for INKmune™, a Natural Killer Therapy, for a Phase I/II Trial in Metastatic Castration-Resistant Prostate Cancer

May 5, 2023 | finance.yahoo.com

INmune Bio First Quarter 2023 Earnings: US$0.36 loss per share (vs US$0.39 loss in 1Q 2022)

See More Headlines

Receive INMB Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for INmune Bio and its competitors with MarketBeat's FREE daily newsletter.

INMB Company Calendar

Last Earnings: 8/07/2023
Today: 9/29/2023
Next Earnings (Estimated): 11/01/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biological products, except diagnostic
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:INMB
CUSIP: N/A
CIK: 1711754
Web: www.inmunebio.com
Phone: (858) 964-3720
Fax: N/A
Employees: 10
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $16.00
High Stock Price Forecast: $16.00
Low Stock Price Forecast: $16.00
Forecasted Upside/Downside: +128.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 1 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($1.47)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-27,300,000.00
Net Margins: -9,532.26%
Pretax Margin: -9,532.26%
Return on Equity: -46.30%
Return on Assets: -34.39%

Debt

Debt-to-Equity Ratio: 0.10
Current Ratio: 4.03
Quick Ratio: 4.03

Sales & Book Value

Annual Sales: $370,000.00
Price / Sales: 341.41
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $3.35 per share
Price / Book: 2.09

Miscellaneous

Outstanding Shares: 18,020,000
Free Float: 11,516,000
Market Cap: $126.32 million
Optionable: Not Optionable
Beta: 1.95

10 Best Cheap Stocks to Buy Now

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Dr. Raymond Joseph Tesi M.D. (Age 67)
Co-Founder, Pres, CEO, Chief Medical Officer & Chairman
Comp: $591.5k

Mr. David J. Moss M.B.A. (Age 53)
CFO, Treasurer & Sec.
Comp: $445.16k

Dr. Mark William Lowdell BSc (Age 60)
FRCPath, MICR, MSc, Ph.D., Chief Scientific Officer & Chief Manufacturing Officer
Comp: $152.01k

Mr. Joshua S. Schoonover Esq.
Assoc. Gen. Counsel

Dr. Christopher J. Barnum
Head of Neuroscience

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

INMB Stock - Frequently Asked Questions

Should I buy or sell INmune Bio stock right now?: 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for INmune Bio in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" INMB shares.
View INMB analyst ratings or view top-rated stocks.
What is INmune Bio's stock price forecast for 2023?: 1 equities research analysts have issued 1-year price objectives for INmune Bio's shares. Their INMB share price forecasts range from $16.00 to $16.00. On average, they predict the company's share price to reach $16.00 in the next twelve months. This suggests a possible upside of 128.2% from the stock's current price.
View analysts price targets for INMB or view top-rated stocks among Wall Street analysts.
How have INMB shares performed in 2023?: INmune Bio's stock was trading at $6.34 at the beginning of 2023. Since then, INMB shares have increased by 10.6% and is now trading at $7.01.
View the best growth stocks for 2023 here.
When is INmune Bio's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023.
View our INMB earnings forecast.
How were INmune Bio's earnings last quarter?: INmune Bio, Inc. (NASDAQ:INMB) posted its quarterly earnings data on Monday, August, 7th. The company reported ($0.36) earnings per share for the quarter. The business had revenue of $0.05 million for the quarter. INmune Bio had a negative trailing twelve-month return on equity of 46.30% and a negative net margin of 9,532.26%.

What other stocks do shareholders of INmune Bio own?: Based on aggregate information from My MarketBeat watchlists, some companies that other INmune Bio investors own include Inovio Pharmaceuticals (INO), VBI Vaccines (VBIV), Advanced Micro Devices (AMD), Cidara Therapeutics (CDTX), Gilead Sciences (GILD), Cisco Systems (CSCO), Vaxart (VXRT), Micron Technology (MU), Novavax (NVAX) and SCYNEXIS (SCYX).
What is INmune Bio's stock symbol?: INmune Bio trades on the NASDAQ under the ticker symbol "INMB."
How do I buy shares of INmune Bio?: Shares of INMB stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is INmune Bio's stock price today?: One share of INMB stock can currently be purchased for approximately $7.01.
How much money does INmune Bio make?: INmune Bio (NASDAQ:INMB) has a market capitalization of $126.32 million and generates $370,000.00 in revenue each year. The company earns $-27,300,000.00 in net income (profit) each year or ($1.47) on an earnings per share basis.
How can I contact INmune Bio?: INmune Bio's mailing address is 1200 PROSPECT STREET SUITE 525, LA JOLLA CA, 92037. The official website for the company is www.inmunebio.com. The company can be reached via phone at (858) 964-3720 or via email at james@haydenir.com.

This page (NASDAQ:INMB) was last updated on 9/29/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial